PE20040158A1 - Sales de nateglinida - Google Patents

Sales de nateglinida

Info

Publication number
PE20040158A1
PE20040158A1 PE2003000246A PE2003000246A PE20040158A1 PE 20040158 A1 PE20040158 A1 PE 20040158A1 PE 2003000246 A PE2003000246 A PE 2003000246A PE 2003000246 A PE2003000246 A PE 2003000246A PE 20040158 A1 PE20040158 A1 PE 20040158A1
Authority
PE
Peru
Prior art keywords
inhibitors
nateglinide
protonated form
angiatidethe
refers
Prior art date
Application number
PE2003000246A
Other languages
English (en)
Spanish (es)
Inventor
La Cruz Marilyn De
Richard Victor Vivilecchia
Paul Allen Sutton
David John Parker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20040158A1 publication Critical patent/PE20040158A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2003000246A 2002-03-11 2003-03-11 Sales de nateglinida PE20040158A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36317802P 2002-03-11 2002-03-11

Publications (1)

Publication Number Publication Date
PE20040158A1 true PE20040158A1 (es) 2004-04-26

Family

ID=27805267

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000246A PE20040158A1 (es) 2002-03-11 2003-03-11 Sales de nateglinida

Country Status (11)

Country Link
US (2) US20050234129A1 (https=)
EP (1) EP1483232A1 (https=)
JP (2) JP2005519949A (https=)
CN (1) CN1274668C (https=)
AR (1) AR038927A1 (https=)
AU (1) AU2003214112A1 (https=)
BR (1) BR0308316A (https=)
CA (1) CA2478599A1 (https=)
PE (1) PE20040158A1 (https=)
TW (1) TW200304813A (https=)
WO (1) WO2003076393A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7449519B2 (en) * 2003-02-18 2008-11-11 Konishi Co., Ltd. Curing resin, method for producing same and curing resin composition
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
HU227073B1 (hu) * 2003-07-10 2010-06-28 Richter Gedeon Nyrt Eljárás királisan tiszta N-(transz-4-izopropil-ciklohexilkarbonil)-D-fenil-alanin (nateglinid) és kristálymódosulatainak elõállítására, valamint a G-kristálymódosulata
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
WO2005016315A1 (en) * 2003-08-14 2005-02-24 Ranbaxy Laboratories Limited Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler
WO2005020979A1 (en) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited A process for the preparation of pharmaceutical compositions of nateglinide
TWI340650B (en) 2004-01-21 2011-04-21 Otsuka Pharma Co Ltd Amine saly of carbostyril derivative
US20060004102A1 (en) * 2004-05-07 2006-01-05 Shlomit Wizel Polymorphic forms of nateglinide
MY147393A (en) 2005-09-14 2012-11-30 Takeda Pharmaceutical Administration of dipeptidyl peptidase inhibitors
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2305239A1 (fr) * 2009-09-24 2011-04-06 Assistance Publique, Hopitaux De Paris Neuroprotection retinienne par des inhibiteurs des canaux ioniques regules par la sous-unite SUR
EP3003327B1 (en) 2013-06-05 2017-08-09 Tricida Inc. Proton-binding polymers for oral administration
CN103417971A (zh) * 2013-08-13 2013-12-04 深圳奥萨医药有限公司 二肽基肽酶抑制剂和b族维生素的药物组合物及用途
RS61409B1 (sr) 2014-12-10 2021-03-31 Tricida Inc Polimeri koji vezuju protone za oralnu primenu opis
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
ES2100291T3 (es) * 1991-07-30 1997-06-16 Ajinomoto Kk Cristales de n-(trans-4-isopropilciclohexilcarbonil)-d-fenilalanina y metodos para prepararlos.
WO2000059865A1 (en) * 1999-04-06 2000-10-12 Ono Pharmaceutical Co., Ltd. 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AU1133901A (en) * 1999-10-08 2001-04-23 Novartis Ag Method of treating metabolic disorders
HUP0600522A2 (en) * 1999-12-23 2006-11-28 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
PE20020323A1 (es) * 2000-08-22 2002-06-13 Novartis Ag COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina

Also Published As

Publication number Publication date
US20090143469A1 (en) 2009-06-04
CN1274668C (zh) 2006-09-13
JP2011006476A (ja) 2011-01-13
JP2005519949A (ja) 2005-07-07
CA2478599A1 (en) 2003-09-18
BR0308316A (pt) 2004-12-28
WO2003076393A1 (en) 2003-09-18
AU2003214112A1 (en) 2003-09-22
EP1483232A1 (en) 2004-12-08
US20050234129A1 (en) 2005-10-20
AR038927A1 (es) 2005-02-02
TW200304813A (en) 2003-10-16
CN1642904A (zh) 2005-07-20

Similar Documents

Publication Publication Date Title
PE20040158A1 (es) Sales de nateglinida
ES2636692T3 (es) Formulación de anticuerpos humanos para tratar trastornos asociados con TNF-alfa
ES2525497T3 (es) Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
UY29759A1 (es) Formulaciones de ibandronato mejoradas
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
PE20081578A1 (es) Formulacion en polvo de valganciclovir
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
AR076864A1 (es) Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos
RU2016135952A (ru) Композиции ингибитора дофа-декарбоксилазы
ES2254078T3 (es) Composicion que comprende teanina para eliminar problemas de comportamiento de las mascotas.
JP2005519949A5 (https=)
AR054448A1 (es) Composiciones farmaceuticas que comprenden acido arsenioso, su sal de sodio y sus derivados destinada al tratamiento de cancer urogenital y de su metastasis
AR029412A1 (es) Forma cristalina
AR057099A1 (es) Una forma cristalina, un proceso de preparacion y composicion farmaceutica
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
AU2003274060A1 (en) Painless injectable compositions containing salt of 2-arylpropionic acids
AR055099A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
NO20082181L (no) Formuleringer av Fispemifen
ES2219633T3 (es) Sal de creatina que tiene eficacia nutricional y terapeutica y composiciones que la contienen.
US20070088086A1 (en) Method of using synthetic L-Se-methylselenocysteine as a nutriceutical and a method of its synthesis
Pokrovskii et al. Comparative study of potential endothelioprotectors and impaza in modeled nitric oxide defi ciency
PE20040724A1 (es) Composicion para la administracion oral de calcitonina
PE20060460A1 (es) Formulaciones solidas de tetrodotoxina que pueden ingerirse por via oral
HN2003000015A (es) Sales estables del acido o acetilsalicilico con aminoacidos basicos i i.
AR044802A1 (es) Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos

Legal Events

Date Code Title Description
FD Application declared void or lapsed